Sapient Capital’s Y-mAbs Therapeutics YMAB Stock Holding History

Sapient Capital’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-43,700	Closed	-$197K	–	401
2025 Q2	$197K	Hold	43,700	–	–	﹤0.01%	363
2025 Q1	$194K	Hold	43,700	–	–	﹤0.01%	354
2024 Q4	$342K	Hold	43,700	–	–	0.01%	286
2024 Q3	$575K	Hold	43,700	–	–	0.01%	246
2024 Q2	$528K	Hold	43,700	–	–	0.01%	231
2024 Q1	$711K	Hold	43,700	–	–	0.02%	208
2023 Q4	$298K	Buy	+43,700	New	+$253K	0.01%	294

Other funds holding YMAB

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sapient Capital's YMAB Position: Q3 2025 in Review

Sapient Capital sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 43,700 shares — an estimated $197K sold.

Sapient Capital first reported a position in YMAB in Q4 2023 and held it in 7 quarters. The position peaked at $711K in Q1 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

Sapient Capital reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
Sapient Capital sold 43,700 Y-mAbs Therapeutics shares in Q3 2025, an estimated $197K.
Sapient Capital first reported a position in Y-mAbs Therapeutics in Q4 2023 and held it in 7 quarters.
Sapient Capital's Y-mAbs Therapeutics position peaked at $711K in Q1 2024.
2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Sapient Capital's 13F filing for Q3 2025, filed 17 Oct 2025.